The Delhi High Court has directed Dr. Reddy's Labs to respond to Novo Nordisk's injunction petition concerning its weight-loss drug, semaglutide (Wegovy). Novo Nordisk alleges patent infringement, prompting the court's action. An IP expert suggests Dr. Reddy's Labs may need to justify its semaglutide exports, as Novo Nordisk's patent is set to expire in March of next year.
RSS News
Economic times
0 thoughts on “Delhi HC seeks Dr Reddy's reply in Novo patent dispute”
Leave a Reply
Your email address will not be published. Required fields are marked *
RECENT NEWS
- Jackie Shroff's daughter Krishna Shroff passed away in two days.
- Karnataka rain: Moderate rainfall expected in Bengaluru on August 7 after overnight rains
- Supreme Court dismisses plea challenging legality of probe process in cash scam case
- Cash-at-home row: SC rejects Justice Yashwant Varma's plea; judge had challenged in-house inquiry
- 'Ready to pay a heavy price to protect farmers...' PM Modi's big statement in the midst of tariff war
